Search
Prazosin
go.drugbank.com/drugs/DB00457ApprovedInvestigationalPrazosin is marketed by _Pfizer_ and was initially approved by the FDA in 1988.[L5828] It belongs to the class of drugs known as alpha-1 antagonists. … Recently, many studies have evaluated the benefits of this drug in controlling the symptoms of post-traumatic stress disorder (PTSD) and associated nightmares.[A176618, A176621, A176624]
Categories: Heterocyclic Compounds, 2-RingSynonyms: 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine, 2-(4-(2-Furoyl)piperazin-1-yl)-4-amino-6,7-dimethoxyquinazolineValdecoxib
go.drugbank.com/drugs/DB00580ApprovedWithdrawnValdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke.
Categories: COX-2 Inhibitors, Selective Cyclooxygenase 2 Inhibitors (NSAIDs)Products: BEXTRA ® 10 MG TABLETAS RECUBIERTAS, BEXTRA®20 MG TABLETAS RECUBIERTASNirsevimab
go.drugbank.com/drugs/DB16258ApprovedInvestigational[A254691] This is due to a modification in the Fc region of nirsevimab that grants it a longer half-time compared to typical monoclonal antibodies. … [L44146,A254571] Compared to [palivizumab], another anti-RSV antibody, nirsevimab shows greater potency at reducing pulmonary viral loads in animal models.
Synonyms: Immunoglobulin g1-kappa, anti-(human respiratory syncytial virus fusion glycoprotein f0 (protein f))human monoclonal antibody.gamma.1 heavy chain (1-456) (human vh (homo sapiens ighv1-69*01(ighd)-ighj4Products: Beyfortus 50 mg Enjeksiyonluk Çözelti İçeren Kullanıma Hazır Enjektör, 5 adet, iğnesiz, Beyfortus 50 mg Enjeksiyonluk Çözelti İçeren Kullanıma Hazır Enjektör, 1 adet, iğnesizHydrocodone
go.drugbank.com/drugs/DB00956ApprovedIllicitInvestigational[T116] It is commonly used in combination with [acetaminophen] to control moderate to severe pain. … Hydrocodone's more potent metabolite, [hydromorphone] has also found wide use as an analgesic and is frequently used in cases of severe pain.
Mixtures: DOXU PLUS 10/250 MG TABLETAS RECUBIERTAS, DOXU® PLUS 10 / 250 MG TABLETAS RECUBIERTASCategories: Heterocyclic Compounds with 4 or More Rings, Cytochrome P-450 SubstratesRanibizumab
go.drugbank.com/drugs/DB01270ApprovedInvestigational[A246399] Ranibizumab was initially approved by the FDA in 2006 [A2301] and by the European Commission (EC) in 2007.[L41429] It is marketed under the brand names LUCENTIS and SUSVIMO. … [L41399] In August 2022, other biosimilars CIMERLI, RAIVISIO, and RANOPTO were approved by the FDA, EC, and Health Canada respectively.[L42625,L43513,L49141]
Products: LUCENTIS 10 MG/ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE, LUCENTIS® 10 MG /ML SOLUCION INYECTABLERibavirin
go.drugbank.com/drugs/DB00811ApprovedInvestigationalThe dual therapy was administered for 48 weeks in patients with genotype 1, 4, 5, and 6, and 24 weeks in patients with genotype 2 and 3 [A19626]. … adjunct therapy to various first-line and second-line combination therapies recommended for each genotypes.
Mixtures: Rebetron Ready To Use Solution (albumin(human)free) (6000000 Iu/ml and 200mg Capsules), Rebetron Solution (albumin (human) Free) (18 Miu Multi-dose Pen / 200mg Capsules)Products: VIRON 400 MG FİLM KAPLI TABLET, 56 ADET, VIRON 600 MG FİLM KAPLI TABLET, 56 ADETBelimumab
go.drugbank.com/drugs/DB08879ApprovedInvestigational[L42630] Belimumab was first approved by the FDA on March 9, 2011,[A251495] making it the newest drug to be approved for the treatment of SLE in more than 50 years. … It is produced by recombinant DNA technology in a murine cell (NS0) expression system.
Products: BENLYSTA 200 MG / 1 ML, BENLYSTA SUBCUTÁNEO 200 MG / 1 MLNatalizumab
go.drugbank.com/drugs/DB00108ApprovedInvestigational[A261331] On August 24, 2023, the first biosimilar to natalizumab, natalizumab-sztn, was approved by the FDA.[L48041] Natalizumab was approved by the European Commission on September 22, 2023. … [L48041] While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy
Synonyms: IMMUNOGLOBULIN G4 (HUMAN-MOUSE MONOCLONAL AN100226 4-CHAIN ANTI-HUMAN INTEGRIN 4), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL AN100226 LIGHT CHAIN, DIMER, IMMUNOGLOBULIN G4 (HUMAN-MOUSE MONOCLONAL AN100226 4-CHAIN ANTI-HUMAN INTEGRIN 4), DISULPHIDE WITH HUMAN-MOUSE MONOCLONAL AN100226 LIGHT CHAIN, DIMERProducts: Tysabri 150 mg SC Enjeksiyonluk Çözelti İçeren Kullanıma Hazır Enjektör (2 adet), TYSABRI 300 MG I.V. INFUZYON ICIN KONSANTRE COZELTI ICEREN FLAKON, 1 ADETRomosozumab
go.drugbank.com/drugs/DB11866ApprovedInvestigationalIn a comparison study of post menopausal women with osteoporosis and a past fracture, romosozumab for 12 months followed by alendronic acid for 12 months was superior to alendronic acid alone for 24 months … Romosozumab prevents bone resorption and induces the formation of bone though it is associated with an increased risk of cardiac death, heart attack, and stroke in one study[L5921,L5924].
Products: EVENİTY 105 MG/1,17 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 2 ADET, EVENITY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 105 MG/1.17 MLVemurafenib
go.drugbank.com/drugs/DB08881ApprovedInvestigational[A31270] Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. … [A31269] It exerts its function by binding to the ATP-binding domain of the mutant BRAF.
Categories: Heterocyclic Compounds, 2-Ring, Cytochrome P-450 SubstratesProducts: ZELBORAF 240 MG FILM KAPLI TABLET ,56 FILM KAPLI TABLET, ZELBORAF ® TABLETAS LACADAS DE 240 MG